1Hanna WM, Kwok K. Chromogenic in-situ hybridization : a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm[J]. Mod Pathol, 2006, 19 (4) : 481-487.
2Russell SD, Blackwell KL, Lawrence J, et al. Independent adju- dication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials[J]. J Clin Oncol, 2010,28 (21) :3416-3421.
3Procter M, Suter TM, de Azambuja E, et al. Longer-term assess- ment of trastuzumab-related cardiac adverse events in the Her- ceptin Adjuvant (HERA) trial[J]. J Clin Oncol,2010,28 (21): 3422-3428.
4Romond EH,Perez EA, Bryant J, et al. Trastuzumab plus adju- vant chemotherapy for operable HER2-positive breast cancer[J]. N Engl J Med, 2005,353 (16) : 1673-1684.
5Piccart-Gebhart M J, Procter M, Leyland-Jones B, et al. Trastuzu- mab after adjuvant chemotherapy in HER2-positive breast can- cer[J]. N Engl J Med, 2005,353 (16) : 1659- 1672.
6Guarneri V, Lenihan D J, Valero V, et al. Long-term cardiac tol- erability of trastuzumab in metastatic breast cancer:the M.D. Anderson Cancer Center experience [J]. J Clin Oncol,2006,24 (25) :4107-4115.
7Carver JR. Management of Trastuzumab-Related Cardiac dysfun- ction[J]. Prog Cardiovasc Dis, 2010,53 (2) : 130-139.
8Perik PJ,Lub-De Hooge MN, Gietema JA,et al. Indium-111-la- beled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer [J]. J Clin Oncol, 2006,24 ( 15 ) : 2276-2282.
9Cardinale D, Colombo A,Torrisi R, et al. Trastuzumab-induced cardiotoxicity:clinical and prognostic implications of troponin Ⅰ evaluation[J]. J Clin Oncol,2010,28(25) :3910-3916.
1Dahabreh IJ,Linardou H,Siannis F,et al.Trastuzumab in the adjuvant treatment of early-stage breast cancer:a systematic review and meta-analysis of randomized controlled trials[].The Oncologist.2008
2Luca Gianni on behalf of the HERA Trial Study Team.Update of the HERA trial at4years’median follow-up[]..2009
3Slamon D,Eiermann W,Robert N,et al.Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel(AC→T)with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab(AC→TH)with docetaxel,carboplatin and trastuzumab(TCH)in HER2positive early breas[]..
4Spielmann M,RochéH,Humblet Y,et al.3-year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients:results of the PACS-04trial[]..
5Romond E H,Perez E A,Bryant J,et al.Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer[].The New England Journal of Medicine.2005
6Piccart-Gebhart MJ,Procter M,Leyland-Jones B,et al.Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer[].New England Journal of Homeopathy.2005
7Smith M,Procter R,Gelber S,et al.2-year follow-up of trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer:a randomised controlled trial[].The Lancet.2007
8Joensuu H,,Kellokumpu-Lehtinen P-L,Bono P,et al.Adjuvant docetaxel or vinorelbine with or without trastuzum-ab for breast cancer[].The New England Journal of Medicine.2006
9Hanna WM,Kwok K.Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm[].Modern Pathology.2006
10TM Suter,N Cook-Bruns,C Barton.Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer[].Breast Journal.2004
4National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology : breast cancer[ S ]. 2014:49.
5Baker J, Ajani .l, Scott： F, et al. DocetaxeI-related? side effects? and their? management[J]. Eur J Oncol Nuts,2009, 13 ( 1 ) : 49 -59.
6LE JEUNNE C, BILLON N, DANDON A, et al. Off-label prescriptions:how to identify them, frame them, announce them and monitor them in practice? [ J] .Therapie, 2013, 68(4) :225-239.
7OU S H,SOO R A, KUBO A, et al.Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-Rearranged (ROSI-, RET-,AXL-, PDGFR-~~-, NTRK1-) non-small cell lung cancer globally? [J] .Front Oncol, 2014,4: 58. doi: 10.3389/fonc. 2014.00058.
8PAK IN D M, BRAY F, FERLAY J, et al. Estimating the world cancer burden: Globocan 2000 [J]. Int J Cancer, 2001,94(2) : 153-156.
9国家药品食品监督管理局.药品说明书和标签管理规定[G].2006-06-01.
10MEHR S R. The complexity of covering off-label use for a multitude of oncology regimens [ J ]. Am J Manag Care, 2012,18(5 Spec No.) :SP242-247.
